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A major challenge in treating acute myeloid leukemia (AML) is the molecular 
heterogeneity of the disease. Previously we showed that interleukin-1 (IL-1), promotes the 
growth of AML cells in ~ 70% of tested primary AML samples. Increased secretion of IL-1 
results in increased levels of IL-1 receptor-associated kinase (IRAK1), an essential mediator of 
innate immunity and inflammatory responses. In this study, we showed overexpression of 
IRAK1 and its activity in AML across various genetic subtypes, and showed that genetic 
knockdown of IRAK1 gene by using inducible short hairpin RNA (shRNA) in AML cell lines 
and primary samples as well as xenograft model showed decrease in viability of leukemic cells. 
To determine the efficiency of the kinase inhibitor pacritinib, computational modeling along with 
engineered mutations showed specificity of pacritinib in binding to IRAK1. In compare to 
quizartinib (a FLT3 inhibitor) and ruxolitinib (a JAK1/2 inhibitor), pacritinib showed a broad 
sensitivity across AML cell lines as well as primary samples in decreasing the cell viability by 
reducing IRAK1 phosphorylation. Pacritinib treatment significantly reduced AML progenitors in 
xenograft model as well. Our data showed important role of IRAK1 in AML survival and how 
inhibition of its activity might provide beneficial therapeutically outcomes among heterogeneous 














Cancer, a top leading cause of mortality, is a major public health problem in the United 
States accounting for one in 4 deaths.1 Among all types of blood cancers, acute myeloid 
leukemia (AML) is the most common leukemia among adults with incident of more than 80% in 
patients of above 18 years old.2 AML is characterized as a genetically heterogeneous disease 
causing the clonal expansion of myeloid progenitors in the bone marrow and peripheral blood. 
Standard-of-care cytotoxic chemotherapy has been the most common treatment for this disease 
despite the fact that more than one third of patients show resistance to the chemotherapy, and the 
majority of patients would be diagnosed with relapsed or refractory disease which causes 
patients to have poor prognosis.3 Although the main cause of relapse is not clear, factors such as 
the substantial molecular heterogeneity inherent to AML disease, the emergence of genetically 
heterogeneous sub-clones, and pro-survival signals from the microenvironment as well as tumor-
intrinsic feedback pathways might account for the hidden sources.3 Thus, understanding the 
molecular mechanisms underlying the disease reveals some complexity of it leading to 
development of effective targeted therapy. 
Some targeted therapies for AML have been developed due to recent whole-genome 
sequencing and expression studies uncovering some of the important heterogeneity in the 
molecular abnormalities driving AML. For example, the discovery of the activating internal 
tandem duplication (ITD) mutations in the FMS-related tyrosine kinase 3 (FLT3), which is 
detected in 20-25% of AML patients, has led to development of small inhibitors such as 
sorafenib and quizartinib.4 As another example, gene-expression studies showed that mutations 
in nucleophosmin (NPM1) are present in 35% of patients with AML and resulted in proposing 





shown to improve the outcomes of chemotherapy for patients harboring this mutation.4,5 On the 
other hand, some mutations such as Janus kinase 2 (JAK2) are found rarely in AML, yet 
profound in other blood cancers such as myeloproliferative neoplasms.6 Although using such 
specific small inhibitors show initial suppression of disease, the rise of secondary mutations 
causes resistance to the treatment. For example, although quizartinib (potent inhibitor of FLT3) 
shows positive results in treatment of AML patients harboring FLT3-ITD mutations, resistance 
develops in a  short time due to signaling events induced by the microenvironment.7 Such these 
events have revealed the importance of inflammatory pathways in cancer initiation, progression, 
and development of resistance.8  
The pro-inflammatory cytokine interleukin-1 (IL-1) is shown to provide expansion signal 
for myeloid progenitors in 67% of AML patients while it suppresses the growth of normal 
progenitors.9 Increased secretion of IL-1 in bone marrow microenvironment leads to activation 
of IL-1 receptor-associated kinase (IRAK1) and p38MAPK (MAPK14) in AML cells. IRAK, a 
central player in inflammatory responses by regulating the expression of various inflammatory 
genes in immune cells, is composed of IRAK-1,-2,-3 and -4, with only -1 and -4 being active 
serine/threonine kinases, and expressed in variety of human immune cell types.10 IRAK signaling 
can be initiated from Toll-like receptors (TLRs) or from the interleukin-1 family receptors (IL-
1R).10 Activation of IL-1R and TLR recruits myeloid differentiation primary response 88 
(MYD88), resulting in activation of IRAK4 and IRAK1.10,11 MYD88 coordinates with IRAK 
family to function as a signaling adaptor protein that activates the TRAF6-mediated NF-κB and 
p38MAPK signaling. 11,12 NF-κB pathway regulates immune and inflammatory responses and 
protects cells from undergoing apoptosis in response to cellular stress, and p38MAPK pathway is 





translational levels. 13,14 Oncogenically, active MYD88 mutations result in activation of IRAK 
signaling and such mutations have been determined in diffuse large B-cell lymphoma 
(DLBCL).15 Suppression of IRAK1 signaling in Waldenström’s Macroglobulinaemia (WM) 
showed promising results as a therapeutic approach.15 Additionally, overexpression of IRAK1 in 
myelodysplastic syndromes (MDS) and all subtypes of T-cell acute lymphoblastic leukemia (T-
ALL) is determined, and inhibition of IRAK1 by small inhibitor or gene knock down causes 
reduced survival of leukemic cells. 15-17 In context of AML, several studies report overexpression 
of IRAK1/4 in the cancerous cells 18,19, establishing the pathway as a candidate target in 
hematopoietic malignancies and emphasizing the need for agents that directly inhibit IRAK1 
activity. 
A previous in vitro profiling of 439 kinases using HotSpot assay found pacritinib, small 
ATP-competitive mycrocyclic molecule, as potent inhibitor of IRAK1, CFS1R, FLT3 and 
JAK2.20-22 Pacritinib is in development as a treatment for myelofibrosis.23,24 To evaluate the 
specificity of pacritinib in binding to IRAK1, computational modeling was performed by 
Agarwal laboratory and 3 residues on IRAK1 protein were identified to be important for 
pacritinib binding: serine 295 (S295) forming a hydrogen bond with an oxygen in pacritinib, 
adjacent glycine 294 (G294), and aspartate 298 (D298) forming a salt bridge with tertiary 
ammonium in pacritinib (Figure 2A). Engineered mutations of IRAK1 to resemble CDK2 was 
made by changing S295 to aspartate (S295D), deletion of G294 (ΔG294), and changing D298 to 
lysine (D298K) (Figure 2B). The mutations conferred pacritinib resistance on IRAK1 with the 
D298K substitution conferring significant loss of pacritinib sensitivity (Figure 2C, 2D), 
confirming pacritinib binding to IRAK1 and not CDK2.  





quizartinib (a FLT3 inhibitor) and ruxolatinib (a JAK2 inhibitor), Agarwal laboratory performed 
drug sensitivity assays using AML cell lines and primary samples (n=46) by culturing cells in 
their respective media for 72 hrs with graded concentrations of inhibitors and measuring cell 
viability by colorimetric MTS-based cell viability assay. Using fitted probit curves, IC50, IC90, 
and AUC values were measured and plotted. In both AML cell lines and primary samples, 
pacritinib showed lower IC50 compared to quizartinib and ruxolitinib (Figure 3A-B, 4A). In 
addition, pacritinib showed a reachable IC90 in primary samples and smaller AUC while AUC is 
correlated with IC50 values (Figure 4B-D).  
The experimental evidences showed pacritinib as potent inhibitor of IRAK1. During this 
study I showed the important role of IRAK1 in regulation AML cell survival using in vitro and 
in vivo evidences, suggesting a rational for clinical trial for this indication. 
Method and Materials 
 
 
Methods and Materials  
Cell lines and primary samples: MOLM-14, CMK, GDM-1, HT-93, and U-937 were 
maintained in RPMI-1640 medium supplemented with 10% FBS. THP-1 was maintained in 
RPMI-1640 medium supplemented with 15% FBS. Culture media was also substituted with 2 
mM L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin. All cell lines were cultured 
at 37°C in 5% CO2. Cell lines used in this study were not cultured for longer than 6 months from 
initial purchase or characterization. Mononuclear cells isolated from 46 primary patient samples 
diagnosed with AML were evaluated according to Institutional Review Board guidelines at 
Oregon Health & Science University and cultured in RPMI-1640 supplemented with 10% FBS, 2 
mM L-glutamine, and 100 U/mL penicillin-streptomycin and 10-4 M -mercaptoethanol. 
shRNA-mediated knockdown: An inducible short hairpin RNA (shRNA) library targeting 
human IRAK1 was obtained from Cellecta, Inc (Mountain View, CA). Lentivirus was generated 
by transfecting 293FT cells using VSV-G envelope plasmid, 8.9 helper plasmid, and FuGENE-6 
reagent. Lentivirus particles were concentrated by ultra-centrifuging the viral supernatant at 28,000 
rpm for 2 hr at 4°C. Primary cells and cell lines were infected with concentrated virus particles in 
the presence of 5 μg/mL polybrene and 1 mM HEPES and centrifuged at 2,500 rpm for 90 minutes 
at 30°C. This was repeated at 24 hr. For stable expression of shRNA, cells were GFP-sorted after 
48 hours of infection and maintained in puromycin. To induce shRNA expression, cells were 
treated with 1 g/ml doxycycline, and the effect of gene knockdown was assessed by quantitative 
PCR, cell viability assay, and immunoblotting.  
Immunoblotting: Upon treatment of AML cell lines or primary samples with inhibitors, 
cells were obtained and lysed using 1X lysis buffer purchased from Cell Signaling (Danvers, MA). 
Standard protocol was used to quantify protein concentration and extraction with SDS buffer and 




SDS-PAGE gel. Proteins were identified using the following antibodies as indicated: p-IRAK1 
(12756), p-FLT3 (3464), p-ERK1/2 (9101), p-p38 (4631), p-STAT5 (9351) (Cell Signaling 
Technology); GAPDH (AM4300) (ThermoFisher); IRAK1 (Santa Cruz Biotechnology); and p-
IRAK1 (SAB4504246) and  -tubulin (T6074) (Sigma Chemicals).  
In vivo Xenograft studies: MOML-14 cells expressing doxycycline inducible IRAK1 
shRNA GFP+ (2x105 cell per mouse) were injected into the tail veins of 4-week old NOD-scid 
IL2Rgnull (NSG) mice purchased from Jackson Laboratories. Mice were monitored by performing 
differential blood counts using Heska Vet ABC blood analyzer (scil Animal Care Company, 
Gurnee, IL) and determining GFP percentage in their peripheral blood using flow cytometry. 
Treatment was started 5 days after the initial injection of cells and after confirmation of equal 
engraftment in peripheral blood (>1%). Pacritinib was suspended in vehicle consisting of 0.5% 
weight/volume methylcellulose (4000 cP) and 0.1% volume/volume TWEEN® 80, and mice 
were treated twice daily by oral gavage at the dose of 150 mg/kg using 100 μL volume. 
Doxycycline was suspended in 1% sucrose at concentration of 5 mg/mL, and mice were treated 
once a day by oral gavage using 100 μL volume (500 μg/mouse). Doxycycline arm of mice were 
also maintained at the chow containing 625 mg/kg doxycycline (Envigo, D11072801). Animals 
were sacrificed at day 18 post treatment. The sizes of their spleens and livers were measured, and 
the cells of spleen, bone marrow, and peripheral blood were utilized to quantitate the leukemia 
burden. The cells were stained for live/dead marker (Fixable Aqua dye, ThermoFisher), 
incubated at 37°C for 30 minutes, and stained for human cell markers using CD13 (PE) and 
CD33 (PE) cell surface antibodies and mouse pan hematopoietic cell surface marker using CD45 
(APC-Cy7) (BD Pharmingen) antibody followed by 1 hr incubation at room temperature. The 










IRAK1 Knockdown has profound effect on growth of AML cells.  
By performing immunoblot on AML primary samples and normal cells, we observed 
elevated expression and activity of IRAK1 in AML (supplemental Figure 1). Upon knocking 
down IRAK1 gene in AML cell lines (MOLM-14 and THP-1) and primary samples using 
doxycycline-inducible shRNA, we observed reduction of IRAK1 expression by 70% in two of 
the three tested hairpins, measured by quantitative PCR and confirmed by immunoblotting 
(Figure 1A, 1B). The IRAK1 knock down reduced cell viability by 80% in MOLM-14 (FLT3-
ITD positive) and 40% in THP-1 (FLT3-ITD negative) cell line (Figure 1C). Also, IRAK1 
knock down in primary samples reduced the viability up to 60% (Figure 1C). To enhance the 
results of knock down in primary samples, two hairpins were combined.  
IRAK1 inhibition by pacritinib suppresses growth of AML cell lines.  
As mentioned above, Agarwal laboratory showed a lower IC50 value for pacritinib 
inhibiting the growth of AML cell lines harboring different genetic abbreviations through drug 
sensitivity assays compared to quizartinib and ruxolitinib which were restricted in their capacity 
to inhibit growth across this panel (Figure 3A-B). The effect of IRAK1 inhibition on downstream 
signaling was determined through immunoblot analysis. In MOLM-14 cell line, all three inhibitors 
reduced phosphorylation of IRAK1 on residue T209 at various levels. Also, pacritinib and 
quizartinib, but not ruxolitinib, reduced phosphorylation of STAT5 and p38 and inhibited 
activation of FLT3-ITD (Figure 3C). Further, pacritinib inhibited IRAK1 activation in CSF1R-
dependent cells GDM-1, JAK3 mutation-positive CMK-1, and MLL-AF9-positive THP1 cells 
(Figure 3C). In addition, pacritinib inhibited IRAK1 in PICALM-AF10-dependent U937 cells that 





quizartinib was tested in MOLM-14 cells, IRAK1 phosphorylation was not inhibited compared to 
pacritinib suggesting IRAK1 might not be the direct target of FLT3 (Supplemental Figure 2).  
Pacritinib has a potent sensitivity profile across a broad range of genetic subtypes in primary 
AML patient samples.  
As mentioned in the introduction, Agarwal laboratory observed a significantly lower 
median IC50 compared with that for quizartinib and ruxolitinib when tested inhibitors against 
primary AML samples (n=46). Through this assay, pacritinib showed a higher response rate (85%; 
39/46) than that observed for either quizartinib (54%; 25/46) or ruxolitinib (11%; 5/46), where 
responsiveness was defined as an IC50 value < 500 nM. Notably, comparison of median IC90 values 
for pacritinib and quizartinib suggested that pacritinib treatment leads to an achievable IC90 as well 
as smaller AUC (Figure 4A-D). Through probit mixed effects population curve modeling on AML 
samples, Agarwal laboratory observed that quizartinib was sensitive in inhibiting growth within 
samples harboring FLT3 mutations whereas pacritinib showed sensitivity for both samples with 
mutant FLT3 and wild type FLT3. Analysis through flow cytometry of primary samples treated 
with pacritinib for 72 hours showed significant reduction in CD34+ progenitors (supplemental 
Figure 3). The effect on IRAK1 inhibition on downstream signaling in AML primary samples was 
determined through immunoblotting in which pacritinib reduced IRAK1 and p38 phosphorylation 
(Figure 4B). In addition, pacritinib reduced IRAK1 phosphorylation in IL-1 and LPS stimulated 
cells.   
Genetic knockdown of IRAK1 or treatment with pacritinib reduces the leukemia burden in 
AML xenograft model in vivo. 
To evaluated the efficacy of genetic knockdown of IRAK1 and pacritinib treatment in vivo, 





scid IL2Rgnull (NSG) mice (Figure 5A). After confirmation of engraftment by measuring GFP+ 
percentage on peripheral blood through flow cytometry at day post injection, mice were treated 
with doxycycline, pacritinib or vehicle. Since MOLM-14 cell are GFP+ and express CD13 and 
CD33, we used GFP positivity and the expression of human CD13/CD33 to quantify the effect of 
treatment on the leukemia burden. We observed that both IRAK1 knock down and inhibition by 
pacritinib reduced leukemia burden from ~76% to ~50% and ~42%, respectively, in the bone 
marrow and ~42% to ~8% and ~10%, respectively, in the spleen (Figure 5B-D). Further, the host 
murine cells in the bone marrow and spleen showed increase measured by GFP- cells or murine 
CD45+ cells. We also observed a significant reduction in spleen and liver sizes (Figure 5E, 5F). 
In addition, slight reduction in white blood counts with no significant differences in platelets, 
hemoglobin, and hematocrit with IRAK1 knockdown or pacritinib treatment was observed 
(Supplemental Figure 4). Overall, these results showed IRAK1 knockdown or inhibition by 
pacritinib reduced leukemia burden in vivo.  




Treatment of AML by inhibiting one of the many molecular events has shown the rapid 
emergence of resistance and secondary mutations. This has brought the attention to the bone 
marrow microenvironment-mediated signaling that might be responsible for such occurrences. 
Here we provide evidence that IRAK1 pathway, a central mediator of innate immunity and 
inflammatory responses, is a therapeutic target across a variety of genetic subtypes in AML.  
We showed that IRAK1 in constitutively active in AML cells by being constitutive 
phosphorylated in different genetic subtypes. Although IRAK1 is overexpressed in AML cells 
compared to healthy cells, no correlation was found between IRAK1 activation and AML 
subtypes suggesting the pathway is uniformly active.  
Our data showed that genetic knockdown of IRAK1 reduces viability of leukemic cells in 
vitro and leukemia burden in vivo significantly. This prompted us to test the efficacy of 
pacritinib as potent inhibitor of IRAK1 introduced by a previous study on kinase profiling. 
Through computational modeling and engineered mutations, Agarwal laboratory showed the 
specificity of pacritinib in binding to IRAK1 and tested this inhibitor in comparison to a FLT3 
inhibitor (quizartinib) and a JAK2 inhibitor (ruxolitinib). Among AML cell lines and 46 primary 
samples, pacritinib showed more sensitivity in reducing the viability of cells harboring different 
genetic mutations. Immunoblotting of different AML cell lines and primary samples showed 
inhibitory effect of IRAK1 on down-stream signaling.  
In vivo experiment of inhibiting activity of IRAK1 showed significant reduction of 
leukemia burden using xenograft model. Interestingly, the effect of pacritinib was much higher 
than knockdown of IRAK1 gene alone, suggesting the ability of pacritinib in inhibiting different 
kinases.  
  Discussion  
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Overall, we provide evidence that innate immunity pathway involving IRAK1 is 
important in AML pathobiology. We showed pacritinib is effective in inhibiting the activity of 
IRAK1. Together these results suggest that IRAK1 can serve as a therapeutic target across 
various genetic subtypes, and therefore further clinical exploration of IRAK1 as a target for 
intervention with pacritinib and newer more specific agents is justified in AML.   
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Figure Legends  
Figure 1. IRAK1 knockdown by shRNA reduces viability of AML cells. AML cell lines 
(MOLM-14, THP-1) and primary AML CD34-positive cells were infected with 3 independent 
inducible IRAK1 shRNAs (-1, -2, -3), and primary AML CD34-positive cells were infected with 
a combination of IRAK1 shRNA hairpins. After 48 hours of infection, cells were sorted for GFP 
positivity, and cells stably expressing IRAK1 shRNA were treated with doxycycline for 48 hr and 
6 days. The effect of knockdown was determined by measuring change in IRAK1 gene expression 
by qPCR (A), western blotting (B), and cell growth by MTS assay after 4 days of doxycycline 
treatment (C). Results shown are representative of 3 independent experiments. 
Figure 2. Structural requirements for pacritinib binding in the IRAK1 kinase 
domain. Agarwal laboratory has determined the (A) molecular model of pacritinib-bound IRAK1. 
Ribbon diagram shows crystal structure-based homology model of IRAK1 kinase domain with 
pacritinib docked in the ATP-binding pocket. Key residues forming favorable interactions with the 
inhibitor are highlighted. (B) Kinase domain alignment of human IRAK family and kinase 
paralogs. Engineered IRAK1 mutations based on pacritinib-resistant CDK2 (DG294, S295D, and 
D298K) are indicated in the image in orange, green, and purple, respectively. (C) Representative 
immunoblot showing phosphorylation of wild-type versus mutant IRAK1 in heterologous 
expression system after short-term treatment with pacritinib. (D) Quantitative assessment of 
pacritinib inhibition of wild-type and mutant IRAK1. Percent inhibition is based on calculation of 
ratio of pIRAK1 to total (Flag) IRAK1 after densitometry of immunoblots. Results shown are 
representative of 3 independent experiments. 
Figure 3. Pacritinib effectively targets AML cell lines harboring a broad range of 
genomic aberrations.  Agarwal laboratory cultured AML cell lines in their respective culture 
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media for 72 hours with graded concentrations of pacritinib, quizartinib, and ruxolitinib from 1.2 
nM to 5000 nM using 2-fold dilution curves. Cell viability was measured by colorimetric MTS-
based cell viability assay. (A) Viability of representative cell lines. Each cell line was tested at 
least in triplicate, and data are represented as mean  SEM. (B) Scatter plot showing cell-based 
IC50 values for pacritinib, quizartinib, and ruxolitinib determined from cell-based assays with 
indicated AML cell lines by Agarwal laboratory. (C) Immunoblot analysis of lysates prepared from 
pacritinib-treated AML cell lines as indicated. Phosphorylation status of IRAK1, p38, STAT5, and 
ERK1/2 are shown before and after pacritinib treatment. GAPDH serves as a loading control. 
Immunoblot analysis of lysates prepared from U937, MOLM14, GDM-1, THP1, and CMK-1 cells 
treated with vehicle (UNT) or 1000 nM pacritinib, quizartinib, or ruxolitinib for 16 hours. 
Phosphorylation status of FLT3, IRAK1, p38, and STAT5 before and after inhibitor treatment are 
shown. α-Tubulin serves as a loading control. Results shown are representative of 3 independent 
experiments. 
Figure 4. Pacritinib treatment showes significant ex vivo efficacy in patient-derived 
primary AML cells. Agarwal laboratory culture freshly processed patient-derived primary AML 
cells for 72 hours with graded concentrations of pacritinib, quizartinib, and ruxolitinib from 1.2 
nM to 10,000 nM using a 2-fold drug dilution. Cell viability was measured by colorimetric MTS-
based assay in triplicate. (A) Scatter plot showing cell-based median IC50 values. (B) Scatter plot 
showing cell-based median IC90 values. (C) Scatter plot showing AUC values. (D) Scatter plot 
showing the correlation between AUC and IC50 values determined by Agarwal laboratory. (E) 
Immunoblot analysis of lysates prepared from mononuclear cells derived from 4 independent 
patients with AML and treated with vehicle (UNT), 200 nM pacritinib or quizartinib as well as 
200 nM pacritinib in the presence and absence of 10 ng/mL IL-1 or LPS for 16 hours. 
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Phosphorylation status of IRAK1, p38, and ERK1/2 before and after inhibitor treatment are shown. 
GAPDH serves as a loading control.  
Figure 5. Genetic targeting of IRAK1 or pacritinib treatment leads to a significant 
reduction in leukemia burden. (A) MOLM-14 cells transduced with the doxycycline (Dox) 
inducible IRAK1 shRNA were transplanted into NSG mice (2x 105 cells /mouse) by tail vein 
injections. 5 days post-engraftment, after confirmation of equal engraftment in peripheral blood 
(>1%), the mice were randomly divided in three groups and treated with vehicle control, or 150 
mg/kg pacritinib twice daily or 500 μg/mouse doxycycline per day by oral gavage. Doxycycline 
arm of mice were also maintained at the chow containing 625 mg/kg doxycycline. All the mice 
were sacrificed 18 days post treatment and MOLM-14 cells engraftment was determined by 
measuring hCD13/CD33, and GFP-positivity and contribution of murine cells were analyzed by 
measuring mCD45 and GFP-negetive cells in bone marrow (B) and spleen (C) by flow cytometry. 
(D) The representative FCAS plots are shown for all the treatment conditions. (E-F) The difference 











































































































AML-5  (RUNX1 T148fs)
CMK (JAK3 A572V)
THP1 (MLL/AF9, NRAS G12D)
HL-60 (NRAS Q61L)
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Figure 4




















AML-36 (FLT3-ITD,NPM1, DNMT3A) AML-18 (FLT3-ITD, NPM1, CEBPA)
PAC (150 mg/kg) 
2X per day
Dox (0.5 mg/mouse) 
1X per Day
Vehicle 2x per day
MOLM-14 IRAK1 shRNA  
 18 days post 
treatment
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Supplemental Figure 2. Pacritinib inhibits phosphorylation of IRAK1 in AML cells 
and quizartinib and pacritinib effectively inhibits phosphorylation of FLT3; 
however, only pacritinib inhibits phosphorylation of IRAK1. FLT3-ITD positive AML 
cell line (MOLM-14) was cultured for 16 hours with indicated concentrations of 
quizartinib and pacritinib. Immunoblot analysis of lysates was performed with indicated 
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Supplemental Figure 3. Pacritinib treatment reduces the viability of primary AML 
progenitors ex vivo. Mononuclear cells derived from primary AML samples (N=4) were 
cultured in media containing RPMI-1640 supplemented with 20% FBS and treated with 
indicated concentrations of pacritinib for 72 hours. Cells were stained with fixable 
viability stain, CD34, and CD38 surface markers. The data was collected by flow 
cytometry and analyzed using FlowJo software. The bar graph showed the fold change 
in viability over untreated control for each subpopulation and is represented as mean ± 
SD. The representative plots showing the percentage of total viable, viable CD34+, 
viable CD34+CD38-, and CD34+CD38+ subpopulations for indicated treatment from 
one AML sample. 
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